The Alliance for Safe Biologic Medicines urged restraint when considering FDA findings suggesting switching studies may not be as vital to support interchangeability.

Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.

Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.

Having relaunched Susvimo for wet AMD, Roche now has the ocular implant under FDA review for approval in two diabetic ophthalmic indications and presented two-year data in those settings.